动脉瘤性蛛网膜下腔出血患者的抗凝治疗:对功能结局的影响——单中心系列与多因素分析
该单中心研究纳入2009年1月至2015年10月收治的480例动脉瘤性蛛网膜下腔出血患者,其中17例(4%)在发病前接受口服抗凝治疗。未抗凝组年龄更轻(P=0.005)、入院临床状况更好(P=0.02)、6个月功能结局良好(mRS 0-2)的比例更高(P=0.02),但多因素logistic回归未将抗凝治疗确定为不良结局的显著独立预测因素。作者结论认为抗凝治疗未被确定为影响功能结局的显著独立因素,因此不应省略治疗,但对已知抗凝患者需谨慎管理。
要点
- 480例动脉瘤性蛛网膜下腔出血患者中17例(4%)发病前接受口服抗凝治疗。
- 未抗凝组较抗凝组年龄更轻(P=0.005)、临床状况更好(P=0.02)、6个月功能结局良好比例更高(P=0.02)。
- 多因素logistic回归未将抗凝治疗确定为不良结局的显著独立预测因素。
核心结论
- 抗凝治疗未被确定为影响蛛网膜下腔出血患者功能结局的显著独立因素,因此不应省略治疗,但对已知抗凝患者需谨慎管理。
研究设计与样本
- 单中心系列研究,纳入2009年1月至2015年10月收治的480例动脉瘤性蛛网膜下腔出血患者,评估患者特征、治疗方式、动脉瘤大小与位置、影像学特征及6个月改良Rankin量表(mRS)功能结局,并按mRS 0-2(良好)与mRS 3-6(不良)分层。
主要发现
- 480例患者中17例(4%)在发病前接受抗凝治疗。
- 未抗凝组患者较抗凝组显著年轻(P=0.005)。
- 未抗凝组患者入院临床状况较抗凝组显著更好(P=0.02)。
- 未抗凝组患者达到良好功能结局(mRS 0-2)的比例较抗凝组显著更高(P=0.02)。
- 多因素logistic回归分析未将抗凝治疗确定为不良结局的显著独立预测因素。
临床怎么用
- 作者认为抗凝治疗未被确定为影响功能结局的显著独立因素,因此不应省略治疗,但对已知抗凝患者需谨慎管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Favorable outcome in patients presenting with aneurysmal subarachnoid hemorrhage (SAH) is determined by several factors. Nevertheless, data on the influence of prior use of oral anticoagulation drugs on functional outcome in patients suffering from SAH are scarce. We therefore analyzed our institutional data. METHODS: From January 2009 to October 2015, 480 patients suffering from aneurysmal SAH were admitted to our institution. Information including patient characteristics, treatment modality, aneurysm size and location, radiologic features, and functional neurologic outcome was assessed and further analyzed. Outcome was assessed according to the modified Rankin Scale (mRS) at 6 months and stratified into favorable (mRS 0-2) versus unfavorable (mRS 3-6). RESULTS: Overall, 17 of 480 patients suffering from aneurysmal SAH were on anticoagulation therapy before ictus (4%). Patients without anticoagulation therapy were significantly younger compared with patients with anticoagulation therapy before SAH (P = 0.005). Furthermore, patients without anticoagulation therapy presented in a significantly better clinical condition compared with patients with anticoagulation therapy before SAH (P = 0.02). Additionally, patients without anticoagulation therapy achieved significantly more often favorable functional outcome compared with patients with anticoagulation therapy before SAH (P = 0.02). However, anticoagulation therapy was not identified as a significant and independent predictor for unfavorable outcome in the multivariate logistic regression analysis. CONCLUSION: Anticoagulation therapy has not been identified as a significant and independent factor influencing functional outcome in patients suffering from SAH. Therefore treatment should not be omitted. Nevertheless, cautious management is necessary in patients with known anticoagulation therapy before SAH.
引用
- Schuss P, Hadjiathanasiou A, Brandecker S, et al. Anticoagulation Therapy in Patients Suffering from Aneurysmal Subarachnoid Hemorrhage: Influence on Functional Outcome-a Single-Center Series and Multivariate Analysis. World Neurosurg. 2016. PMID: 28011358. doi:10.1016/j.wneu.2016.12.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。